IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 1 5 2001

TECH CENTER 1600/2900

In re application Application No.

Quingping Jiang et al.

09/626,566

Filed

July 27, 2000

For

NOVEL CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC

ENZYMES AND THEIR USE IN ASSAYS

Examiner

(Not Assigned)

Attorney's Docket

CCDLT-300XX

Group Art Unit:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope Commissioner addressed to: Assistant for Patents, Washington, 3/12/01

D.C. 20231 on

Arthur S. Morgenstern Registration No. 28,244 Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

الكيسان

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Informátion Disclosure Statement.

[] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

Application No. 09/626,566 Filed: July 27, 2000 Group Art Unit: 1645

- [] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
 - [] a statement under 37 CFR § 1.97(e); or
 - [] the fee set forth in $\S 1.17(p)$.

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(i).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[X] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Art was cited in PCT International Search Report mailed 2/1/2001, in International Application No. PCT/US00/20429 filed 7/27/2000.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a

Application No. 09/626,566 Filed: July 27, 2000 Group Art Unit: 1645

counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

QINGPING JIANG ET AL.


14

Arthur S. Morgenstern Registration No. 28,244 Attorney for Applicants

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

ASM/jds Enclosure 245378



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE				ATTY. DOCKET NO.		APPLICATION NO.		
(REV. 8-83) PATENT AND TRADEMARK OFFICE				CCDLT-300XX		09/626,566		
INFORMATION DISCLOSURE CITATION						RECEIVED		
OIPE (Use several sheets if necessary)				MAR 1 5 2001				
				APPLICANT:				
MAR 1 4 2001				Qingping Jiang et #ECH CENTER 1600/2900				
				FILING DATI		GROUP		
- WA				July 27, 2000 1645				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAM	E	CLASS	SUBCLASS	FILING D APPROPE	
	4,810,636	3/7/89	Core	у	435	14		
	5,656,426	8/12/97	Law et	Law et al.		6		
		 						
		ļ						
		 						
		FOREIGN PAT	ENT DOCUME	ENTS				
	DOCUMENT NUMBER	DATE	COUNT	RY	CLASS	SUBCLASS TRANSLATION		ATION
							YES	NO
· · · · · · · · · · · · · · · · · · ·	7=							
	OTHER DOCUM	MENTS (including	Author, Title, Do	ate, Pertinent Po	iges, Etc.)	l <u></u>		_
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) Renault, Jean, et al., "Héterocycles à fonction quinone. I. Acridinediones-1,4 à action antitumorale potentielle"; Eur. Jour. of Medicinal Chemistry - Chimica Therapeutica, vol. 16, no. 1, JanFeb., 1981-16, pp. 24-34.								
				3/12/ 3/				
EXAMINER	_L		DA	TE CONSIDER	RED			
*EXAMINER:	Initial if citation considered, whether or n			1PEP 609; Draw	line through	citation if not ir	conforman	ce and
not considered.	Include copy of this form with next comm	unication to applic	ant.					